Author

Mona Darwish

Institution: Acadia Pharmaceuticals (United States)

Observed institution: Acadia Pharmaceuticals (United States)

ORCID: 0009-0004-8005-4451

Observed ORCID: 0009-0004-8005-4451

OpenAlex ID: A5136383664

An Open‐Label Study Investigating the 5‐HT 2A Receptor Occupancy of Remlifanserin (ACP‐204) With the PET Radioligand [ 18 F]Altanserin in Healthy Male Participants

2026 · Ethan S. Burstein, Christine Sandiego, et al. · Clinical Pharmacology in Drug Development

Development of ACP-711, a Selective Modulator of GABA-A Receptor α3, for Essential Tremor: Use of First-in-Human Phase 1 Pharmacokinetics and Pharmacodynamics to Identify Target Dose/Exposure (P7-16.007)

2026 · Mona Darwish, Nancy Lin, et al. · Neurology

Pimavanserin for Irritability in Children and Adolescents With Autism Spectrum Disorder: Phase 2 Randomized Trial

2026 · Dragana Bugarski-Kirola, Robert K. Hofbauer, et al. · Journal of the American Academy of Child & Adolescent Psychiatry

Works count: 3

Citation count:

H-index:

I10-index: